Abstract
Tacrolimus is an immunosuppression drug widely used for prevention of allograft rejection in kidney and liver transplantations. The once-daily extended-release tacrolimus (LCP-Tac) is a novel formulation for tacrolimus, differentiated by using the MeltDose technology which was designed to enhance the bioavailability of drugs with low water solubility. This study assessed the economic impact of the use LCP-Tac compared with other once-daily extended-release tacrolimus (PR-Tac) and with twice-daily immediate-release tacrolimus (IR-Tac) in patients with kidney or liver transplantation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.